Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × niraparib × CNS × Clear all

Phase

Phase 2 5 Phase 1 3 Phase EARLY_PHASE1 2 Phase 3 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5 Genitourinary 4 Other solid neoplasm 3 Breast 3 Gastrointestinal 2 Tumor-Agnostic 1 Thoracic 1 Head & Neck 1 CNS 1

Conditions

Interventions

Temozolomide 88 Radiotherapy 38 Bevacizumab 28 Carboplatin 21 Irinotecan 17 pembrolizumab 15 Radiosurgery 15 Nivolumab 14 Radiation 13 Magnetic Resonance Spectroscopy 9 Cyclophosphamide 8 Trastuzumab 7 Surgical Procedures, Operative 7 Pemetrexed 7 Paclitaxel 7 Specimen Handling 6 Radiotherapy, Intensity-Modulated 6 Ipilimumab 6 Interleukin-2 6 Filgrastim 6 Everolimus 6 Erlotinib Hydrochloride 6 Carmustine 6 fludarabine 5 Vorinostat 5 Melphalan 5 Lomustine 5 IL13-PE38 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 Gemcitabine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06258018 2024-08-30

ONC-2022-001

Istituto Clinico Humanitas

Phase 1/2 Not yet recruiting

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡